Gemlin-
By 2016, the same author (Ost) had updated his findings. Unfortunately, he found that within 3 years, 69% had more distant mets, and after 5 years, 85% of men who'd had SBRT treatment of solitary metastases, had recurrent metastases in different places. Did it slow it down? It's hard to conclude that, given the slow natural progression at first.
SBRT for oligometastatic recurrenceTake Mel (Compiler) as an example: Two years ago, a single LN met was discovered. 2 years later, there is still only the one met (with no treatment other than iADT). This is a typical progression pattern - very slow at first, accelerating later. Ost found that
with spot treatment, the median time to detection of the next distant met was 21 months. But this is probably no different from the time
without spot treatment. It's impossible to conclude that spot treatment accomplishes anything without a randomized control. And even if it does delay the detection of the next met for a couple of months, does it increase survival? Detectable mets are just the tip of the iceberg.